The US Food and Drug Administration (FDA) has approved naloxegol (Movantik, AstraZeneca Pharmaceuticals), a peripherally acting opioid receptor antagonist, for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain. OIC is a common adverse effect of opioid use. An estimated 40% to 80% of patients receiving long-term opioid therapy experience OIC, which […]
Read MoreSpinal manipulation therapy plus home exercises is more effective than home exercises alone for treating back-related leg pain, according to a study in the Annals of Internal Medicine. Nearly 200 patients with subacute or chronic back-related leg pain were randomized to either spinal manipulation plus home exercises and advice or home exercises and advice alone […]
Read MoreAuthors: Dodick DW et al., Lancet Neurol 2014 Sep 13:885 A phase II study of a monoclonal antibody shows great promise for the first specific migraine-prevention therapy. Calcitonin gene-related peptide (CGRP) has been a long-standing therapeutic target of interest in migraine. Small-molecule CGRP receptor antagonists demonstrated effectiveness for the treatment of acute migraine attacks, but […]
Read MorePublished in J Neurosurg Anesthesiol. 2014 Oct;26(4):369-76 Authors: Davis N et al Abstract The effect of anesthetic technique on postoperative outcomes remains in question. This systematic review compares the role of regional versus general anesthesia, with a particular focus on postoperative cognitive function. Potentially relevant articles were identified by searching publicly available computerized databases for […]
Read MorePublished in J Neurosurg Anesthesiol. 2014 Aug 20 Authors: Hertle DN et al BACKGROUND: Disturbed brain metabolism is a signature of primary damage and/or precipitates secondary injury processes after severe brain injury. Sedatives and analgesics target electrophysiological functioning and are as such well-known modulators of brain energy metabolism. Still unclear, however, is how sedatives impact […]
Read More